EDN1, endothelin 1, 1906

N. diseases: 679; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE This study sought to find a vaccine against endothelin-1 (ET-1) receptor type A (ETAR) for treating PAH. 31118151 2019
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE The dual antagonist to both endothelin-1 type A and B receptors, Macitentan, has been approved for clinical management of pulmonary arterial hypertension while little is known about the secondary effect of the drug on spine. 30911541 2019
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Thus, the prototypes MIL-89 and MIL-89 PEG with core capacity suitable to accommodate PAH drugs are relatively non-toxic and may have the added advantage of being anti-inflammatory and reducing the release of endothelin-1. 28447910 2019
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Exposure of control PASMC and PAEC to ET-1 fully mimicked the PAH cells phenotype, thus confirming that ET-1 is implicated in both metabolism and angiogenesis abnormalities in PAH. 29064353 2019
Idiopathic pulmonary arterial hypertension
0.100 AlteredExpression disease BEFREE The regulation of ET-1 by iron was also demonstrated in healthy humans exposed to hypoxia and in PASMCs from PAH patients with mutations in bone morphogenetic protein receptor type II. 31152133 2019
Idiopathic pulmonary arterial hypertension
0.100 AlteredExpression disease BEFREE Bucindolol attenuates the vascular remodeling of pulmonary arteries by modulating the expression of the endothelin-1 A receptor in rats with pulmonary arterial hypertension. 29710468 2018
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE During the last thirty years since the discovery of endothelin-1, the therapeutic strategy that has evolved in the clinic, mainly in the treatment of pulmonary arterial hypertension, is to block the action of the peptide either at the ET(A) subtype or both receptors using orally active small molecule antagonists. 29947527 2018
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE We demonstrated that treatment with magnolol reduces the development of PAH induced by pneumonectomy and monocrotaline in rats, and suppressing Ang II and ET-1-mediated processes may contribute to its protective effects. 30466619 2018
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Pulmonary vascular remodeling in pulmonary arterial hypertension involves perturbations in the nitric oxide (NO) and endothelin-1 (ET-1) pathways. 30260284 2018
Idiopathic pulmonary arterial hypertension
0.100 AlteredExpression disease BEFREE Moreover, the increased protein expression of endothelin-1 (ET-1) and ET<sub>A</sub> receptor (ET<sub>A</sub>R), superoxide overproduction, and activation of Akt/ERK1/2/GSK3[Formula: see text]/[Formula: see text]-catenin pathway that occurred in the lungs of PAH rats were markedly reversed by BE treatment. 29737212 2018
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Unraveling endothelin-1 induced hypercontractility of human pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension. 29649319 2018
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Some biomarkers play important roles in the endothelial dysfunction of patients with pulmonary arterial hypertension (PAH), including nitric oxide (NO), endothelin-1 (ET-1), asymmetric dimethylarginine (ADMA), galectin-3 (Gal-3), B-type natriuretic peptide (BNP), and uric acid (UA). 28608969 2017
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE The management of PAH has also become more complex, and numerous drugs are now approved that target the endothelin 1, nitric oxide, and prostacyclin pathways. 28593996 2017
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE The effect of exercise training on oxidative stress, metabolism, and markers of nitric oxide (NO) and endothelin-1 (ET-1) was analyzed in the lung tissue of rats with PAH induced by monocrotaline (MCT).Twenty-four Wistar rats were divided into four groups (5-7 animals): sedentary control (SC), sedentary MCT (SM), trained control (TC), and trained MCT (TM). 28181133 2017
Idiopathic pulmonary arterial hypertension
0.100 AlteredExpression disease BEFREE In PAECs isolated from patients with pulmonary arterial hypertension, microRNA (miR)-98 expression was reduced, and ET-1 protein levels and proliferation were increased. 26098770 2016
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Modafinil improved PAH by vasorelaxation and a decrease in medial thickening via ET-1, ERA, and KCa3.1 down regulation. 26959484 2016
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Treatment of PASMCs with the PAH mediators platelet-derived growth factor (PDGF), serotonin, H2O2, endothelin-1, and IL-6 caused significant increases in calpain activity, cell proliferation, and collagen-I protein level without changes in protein levels of calpain-1 and -2. 26248159 2016
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. 26252367 2015
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Furthermore, important molecular pathways that are central to the pathogenesis of pulmonary arterial hypertension are reviewed, including nitric oxide, prostacyclin, endothelin-1, reactive oxygen species, and endothelial and smooth muscle proliferation. 24951762 2014
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Reflecting increased smooth muscle constriction in cells from PAH subject, Ca(2+) influx in response to endothelin-1 (ET-1) increased in all the PAH PASMC populations relative to the normal donor control cells. 22688668 2013
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE Endothelin-1 is a potent endogenous vasoconstrictor, which is considered to be central to many of the events that lead to PAH, and is an important therapeutic target in the treatment of the condition. 22960172 2012
Idiopathic pulmonary arterial hypertension
0.100 GeneticVariation disease BEFREE Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. 21773759 2012
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE The endothelin-1 (ET-1) pathway mediates vasoconstriction and is an established target of pulmonary arterial hypertension (PAH) therapy. 21838752 2012
Idiopathic pulmonary arterial hypertension
0.100 Biomarker disease BEFREE In the present study we investigated the ratio of circulating nitric oxide to endothelin-1 in patients with both SSc and PAH, and determined whether polymorphisms in NOS2 (the nitric oxide synthase 2 gene) are associated with susceptibility to PAH. 16813666 2006